Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Research analysts at HC Wainwright issued their Q1 2024 earnings estimates for shares of Cardiol Therapeutics in a note issued to investors on Monday, April 22nd. HC Wainwright analyst V. Bernardino forecasts that the company will post earnings of ($0.06) per share for the quarter. HC Wainwright has a "Buy" rating and a $9.00 price objective on the stock. The consensus estimate for Cardiol Therapeutics' current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for Cardiol Therapeutics' Q2 2024 earnings at ($0.05) EPS, Q3 2024 earnings at ($0.05) EPS, Q4 2024 earnings at ($0.04) EPS, FY2024 earnings at ($0.20) EPS, FY2025 earnings at ($0.25) EPS, FY2026 earnings at ($0.34) EPS, FY2027 earnings at ($0.09) EPS and FY2028 earnings at $0.43 EPS.
Cardiol Therapeutics Trading Down 4.3 %
Shares of Cardiol Therapeutics stock traded down $0.08 during trading on Wednesday, hitting $1.76. 199,799 shares of the company were exchanged, compared to its average volume of 355,600. The firm has a market capitalization of $120.17 million, a P/E ratio of -5.30 and a beta of 0.95. The firm's fifty day moving average price is $1.68 and its 200 day moving average price is $1.20. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.36 and a quick ratio of 4.36. Cardiol Therapeutics has a 1-year low of $0.55 and a 1-year high of $2.17.
Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) last released its quarterly earnings data on Monday, April 1st. The company reported ($0.09) EPS for the quarter.
Institutional Trading of Cardiol Therapeutics
A hedge fund recently raised its stake in Cardiol Therapeutics stock. Laird Norton Trust Company LLC raised its stake in Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) by 63.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 100,000 shares of the company's stock after buying an additional 38,673 shares during the quarter. Laird Norton Trust Company LLC owned about 0.15% of Cardiol Therapeutics worth $90,000 at the end of the most recent reporting period. Institutional investors own 12.49% of the company's stock.
About Cardiol Therapeutics
(
Get Free Report)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis.
Featured Stories
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
